Sugi Predict

Sugi Predict / Compounds / SCHEMBL407484

SCHEMBL407484

SCHEMBL407484

O=C(O)/C=C/c1ccc(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.58
▸ CA12 O43570 4/20 0.58
▸ CA1 P00915 4/20 0.58
▸ CA2 P00918 4/20 0.58
▸ CA9 Q16790 4/20 0.58
▸ HSD17B10 Q99714 3/20 0.58
▸ CA3 P07451 3/20 0.58
▸ CA4 P22748 3/20 0.58
▸ CA6 P23280 3/20 0.58
▸ CA5A P35218 3/20 0.58
▸ CA7 P43166 3/20 0.58
▸ CA14 Q9ULX7 3/20 0.58
▸ CA5B Q9Y2D0 3/20 0.58
▸ AKR1B10 O60218 2/20 0.58
▸ AKR1B1 P15121 2/20 0.58
▸ DPP4 P27487 2/20 0.58
▸ HDAC3 O15379 2/20 0.58
▸ HDAC4 P56524 2/20 0.58
▸ HDAC1 Q13547 2/20 0.58
▸ HDAC7 Q8WUI4 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29389045 1.00 KDM4E (0.58) KDM4ECA12CA1CA2CA9
SCHEMBL407485 1.00 KDM4E (0.58) KDM4ECA12CA1CA2CA9
Hydrochloric Acid SCHEMBL27954236 0.98 KDM4E (0.56) KDM4ECA12CA1CA2CA9
SCHEMBL3572968 0.86 HSD11B1 (0.61) CA12CA1CA2CA9ALDH1A1
SCHEMBL3572966 0.86 HSD11B1 (0.61) CA12CA1CA2CA9ALDH1A1
SCHEMBL13811028 0.85 NPSR1 (0.56) KDM4ECA12CA1CA2CA9
SCHEMBL4610385 0.85 KDM4E (0.70) KDM4ECA12CA1CA2CA9
SCHEMBL15527953 0.85 NPSR1 (0.56) KDM4ECA12CA1CA2CA9
SCHEMBL4610390 0.85 KDM4E (0.70) KDM4ECA12CA1CA2CA9
SCHEMBL16345020 0.83 NPSR1 (0.54) KDM4ECA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 526 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402930-A1 USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS PRG S&TECH INC. (KR) 2022-12-22 — — US claimed
EP-4056573-A1 USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS PRG S&Tech Inc. (KR) 2022-09-14 — — EP claimed
CN-114929711-A Use of novel compounds for preventing, ameliorating or treating amyotrophic lateral sclerosis PRG科技株式会社 2022-08-19 — — CN claimed
CN-110894184-B Green and environment-friendly ticagrelor intermediate preparation method 安徽一帆香料有限公司 2022-02-18 — — CN claimed
WO-2021086101-A1 USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS (주)피알지에스앤텍 2021-05-06 — — WO claimed
CN-112441990-A Bisamide compound containing 3, 4-dichloroisothiazole heterocycle, and preparation method and application thereof 江西天宇化工有限公司 2021-03-05 — — CN claimed
CN-112126094-A Ultraviolet aging resistant solar cell back panel film and preparation method thereof 程朝刚 2020-12-25 — — CN claimed
CN-110894184-A Green and environment-friendly ticagrelor intermediate preparation method 安徽一帆香料有限公司 2020-03-20 — — CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 — — US claimed
EP-1429768-B1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA (DE) 2016-11-16 — — EP claimed
WO-2005102503-A1 PERVAPORATION COMPOSITE MEMBRANES MCMASTER UNIVERSITY (CA) 2005-11-03 — — WO claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-6919325-B2 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-07-19 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
JP-2003535072-A — — 2003-11-25 — — JP claimed
US-20030130300-A1 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 — — US claimed
US-20030120105-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives ASTRAZENECA AB (SE) 2003-06-26 — — US claimed
EP-1292561-A1 PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES AstraZeneca AB (SE) 2003-03-19 — — EP claimed
WO-2001092200-A1 PROCESS FOR THE PREPARATION OF CYCLOPROPYL CARBOXYLIC ACID ESTERS AND DERIVATIVES ASTRAZENECA AB (SE) 2001-12-06 — — WO claimed
US-5985927-A Medicaments for the selective treatment of tumor tissues KREUTZ WERNER (DE) 1999-11-16 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS KDM4E 2134/4885CA12 4479/4885CA1 4047/4885
US-20030120105-A1 Process for the preparation of cyclopropyl carboxylic acid esters and derivatives MCCC2, DHPS, CYP3A4 KDM4E 857/4885CA12 716/4885CA1 615/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 KDM4E 1567/4885CA12 891/4885CA1 139/4885
US-20220402930-A1 USE OF NOVEL COMPOUND, FOR PREVENTING, IMPROVING OR TREATING AMYOTROPHIC LATERAL SCLEROSIS SOD1, SLC75A1, SLC43A1 KDM4E 4446/4885CA12 4846/4885CA1 4003/4885
US-20030130300-A1 Respiratory system disorders; synergistic mixtures ADRB3, ADRB1, CHRM3 KDM4E 4788/4885CA12 2169/4885CA1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.